ANVISA Approves Gene Therapy for Duchenne Muscular Dystrophy
QR Group analyzes the impact of the arrival of Elevidys in Brazil and the advancement of gene therapy regulation In July 2024, the National Health Surveillance Agency (ANVISA) approved Elevidys (delandistrogene moxeparvovec-rokl), the first gene therapy indicated to treat Duchenne muscular dystrophy (DMD) in Brazil. The drug is manufactured by Sarepta Therapeutics and had already […]
